> ## Content Index
> Fetch the complete content index at: https://www.biostockinfo.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# BIOTECH CATALYST AI SCANNER — October WK
- URL: https://www.biostockinfo.com/biotech-catalyst-ai-scanner-october-wk/
- Published: 2026-10-12T10:19:12.000Z
- Updated: 2026-10-12T10:19:12.000Z
- Author: Alex
- Tags: AI, Biotech Catalysts, Biotech Investing, Machine Learning

BIOSTOCKINFO / CATALYST SCANNER

Scan date 2026-10-12 · 10 featured · 10 watchlist

## The tape

XBI closed October 9 at 153.77, slipping 0.4% over one week, 3.5% over one month, and 3.3% over three months, while maintaining a 26.5% gain year to date and sitting 9.3% below its 52-week high of 169.55\. In contrast, the S&P 500 (SPY) closed at 778.57, rising 1.2% over one week, 2.1% over one month, 3.1% over three months, and 14.0% year to date, just 0.1% off its 52-week high of 779.09\. The performance gap demonstrates sector-specific lagging across biotech against broader equity resilience.

Breadth remains muted, with only 36% of the 5,545 tracked U.S. small and mid caps closing above their 20-day moving average on October 9\. Weak underlying participation creates a difficult backdrop for catalyst-driven names, leaving binary events prone to distribution even on positive pipeline announcements.

The US 10-year Treasury yield stood at 5.24% on October 9, easing 3 basis points over one week but up 67 basis points over three months, within a 52-week range of 3.95% to 5.31%.

## This week at a glance

| TICKER            | CATALYST                            | DATE                       | RANK |
| ----------------- | ----------------------------------- | -------------------------- | ---- |
| [**NRXP**](#NRXP) | GDUFA, ketamine                     | Nov 10, 2026               | 85   |
| [**ACRS**](#ACRS) | Topline Data, bosakitug             | Fourth Quarter 2026        | 84   |
| [**RZLT**](#RZLT) | Topline Data, ersodetug             | this quarter               | 84   |
| [**ZURA**](#ZURA) | Topline Data, tibulizumab           | Q4 2026                    | 82   |
| [**NKTX**](#NKTX) | Conference Presentation, NKX019     | Nov 9, 2026                | 82   |
| [**PHAT**](#PHAT) | Topline Data, VOQUEZNA (vonoprazan) | fourth quarter of 2026     | 79   |
| [**TNYA**](#TNYA) | Interim Data, TN-401                | fourth quarter of the year | 78   |
| [**TARA**](#TARA) | Interim Data, choline chloride      | in 4Q 2026                 | 78   |
| [**FBIO**](#FBIO) | Topline Data, Triplex               | late 2026                  | 77   |
| [**ZBIO**](#ZBIO) | Topline Data, obexelimab            | 4Q 2026                    | 77   |

Top 10 names by scanner score, highest first. Rank is the scanner’s score out of 100.

## Featured

### NRXP — NRx Pharmaceuticals

| CATALYST**Nov 10, 2026**Regulatory | RANK**85**          | PRICE**$2.85**\-16% 20d |
| ---------------------------------- | ------------------- | ----------------------- |
| CAP**$123M**(43M sh)               | CASH**$42M**\~25 mo |                         |

Filing warning

**The FDA is scheduled to act on the Abbreviated New Drug Application for preservative-free ketamine NRX-100 on Nov 10, 2026.** Clearance decides generic commercialization in an active drug shortage market ahead of a planned 2027 branded depression application.

**Company.** NRx develops NMDA-platform therapies for central nervous system disorders. It generates clinic revenue but has no approved product sales. Its pipeline includes an NRX-100 depression application targeting 2027 approval and five million commercial units currently in manufacturing.

**Science & competition.** Ketamine acts as an NMDA receptor antagonist to trigger rapid synaptic connections. Rivals include Esketamine (Spravato) (Johnson & Johnson (Janssen), FDA-approved 2019 for TRD), Dextromethorphan/bupropion (Auvelity) (Axsome Therapeutics, FDA-approved 2022 for MDD), Gepirone ER (Exxua) (Fabre-Kramer Pharmaceuticals, FDA-approved 2023 for MDD), and COMP360 (synthetic psilocybin) (COMPASS Pathways, Phase 3 for TRD). Standard of care relies on antidepressant medication, psychotherapy, and brain-stimulation therapies.

Competition sources

Sources: [Characteristics of Trials Preceding FDA Approval of Novel Psychiatric Drugs | Research, Methods, Statistics | JAMA Network Open | JAMA Network](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829552?utm%5Fsource=openai) · [FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia | FDA](https://www.fda.gov/news-events/press-announcements/fda-approves-first-non-antipsychotic-drug-treat-agitation-associated-dementia?utm%5Fsource=openai) · [Drug Trials Snapshots: EXXUA | FDA](https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-exxua?utm%5Fsource=openai) · <https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/a8-kdated7july2026ex991.htm?utm%5Fsource=openai>

**Why it could work.** The FDA downgraded a vial deficiency from major to minor following manufacturer attestation. In a licensed Columbia University study, 55% of patients on intravenous ketamine had at least a 50% reduction in suicidality, versus 30% on an active comparator.

**Why it could fail.** The FDA previously cited a major packaging deficiency regarding the vial's luer-lock component, and unresolved manufacturing issues could prompt a Complete Response Letter or extended delays.

**Recent development.** On September 29, 2026, NRx’s subsidiary received an $11.2 million DARPA prime contract, with $6.7 million initially obligated, to conduct an FDA-approved trial evaluating SPARC-TMS combining NRX-101 with robotic neuro-navigated transcranial magnetic stimulation ([sec.gov](https://www.sec.gov/Archives/edgar/data/1719406/000143774926032042/nrxp20261005%5F8k.htm?ref=biostockinfo.com)). The non-dilutive award funds a separate psychiatric device program distinct from the generic ketamine review.

**Filing flag.** The August 17, 2026 filing states FDA had identified a major deficiency concerning the vial's luer-lock component and requested a manufacturer attestation; the company said it submitted the attestation. The September 16, 2026 filing reports the related amendment was reclassified from major to minor, not that the ANDA was approved.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=NRXP&ref=biostockinfo.com)

### ACRS — Aclaris Therapeutics

| CATALYST**Fourth Quarter 2026**Data readout | RANK**84**           | PRICE**$3.83**\-28% 20d |
| ------------------------------------------- | -------------------- | ----------------------- |
| CAP**$564M**(147M sh)                       | CASH**$193M**\~37 mo |                         |

**Aclaris expects topline results from its 109-patient Phase 2 trial of bosakitug in atopic dermatitis in Fourth Quarter 2026 (company's words; quarter-level precision).** The readout determines whether upstream cytokine blockade justifies registrational Phase 3 clinical development.

**Company.** Aclaris develops pipeline assets for immuno-inflammatory diseases. It has no approved commercial product revenue. Beyond lead candidate bosakitug, the pipeline includes two Phase 1b proof-of-concept readouts, alongside licensing pacts with Eli Lilly and Sun Pharma.

**Science & competition.** Bosakitug is a monoclonal antibody blocking thymic stromal lymphopoietin to shut down epithelial inflammatory alarms. Rivals include Dupilumab (Regeneron/Sanofi, 2017), Upadacitinib (AbbVie, 2022), Abrocitinib (Pfizer, 2022), Tralokinumab (LEO Pharma, 2023), Lebrikizumab (Lilly, 2024), and Nemolizumab (Galderma, 2024). Standard of care includes topical corticosteroids, emollients, and targeted systemic therapies like dupilumab or oral JAK inhibitors.

Competition sources

Sources: <https://www.sec.gov/Archives/edgar/data/1121404/000119312526316771/d150377dex992.htm?utm%5Fsource=openai> · [Eczema types: Atopic dermatitis diagnosis and treatment](https://www.aad.org/public/diseases/eczema/types/atopic-dermatitis/treatment?utm%5Fsource=openai)

**Why it could work.** Prior Phase 2a testing showed 9 of 22 patients achieved EASI-75 by week 26\. Upstream TSLP blockade tackles epithelial alarm signaling across broad disease subtypes.

**Why it could fail.** Industry-wide TSLP inhibition has shown mixed atopic dermatitis efficacy, and elevated placebo responses across 109 patients could obscure modest eczema score improvements.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=ACRS&ref=biostockinfo.com)

### RZLT — Rezolute

| CATALYST**this quarter**Data readout | RANK**84**          | PRICE**$4.87**+15% 20d |
| ------------------------------------ | ------------------- | ---------------------- |
| CAP**$471M**(97M sh)                 | CASH**$87M**\~14 mo |                        |

BTD Filing warning

**Rezolute expects Phase 3 upLIFT topline results evaluating ersodetug in up to 16 hospitalized tumor hyperinsulinism patients this quarter (company's words; quarter-level precision):** BTD**.** The open-label study determines whether the antibody can support a marketing application for life-threatening tumor-induced hypoglycemia.

**Company.** Rezolute develops targeted therapies for rare metabolic conditions. It has no commercial product sales. Its lead asset ersodetug is being evaluated across tumor hyperinsulinism in the upLIFT trial and congenital hyperinsulinism in the Phase 3 sunRIZE program.

**Science & competition.** Ersodetug is a monoclonal antibody binding allosterically to insulin receptors to dampen signaling. Teva markets Diazoxide (Proglycem) (FDA-approved; label includes secondary hypoglycemia from hyperinsulinism associated with inoperable islet-cell tumors). Standard of care consists of surgical tumor removal when feasible, alongside continuous intravenous glucose infusions, dextrose, or diazoxide.

Competition sources

Sources: [Glucagon Agents Summary](https://www.hhs.texas.gov/sites/default/files/documents/jan-2024-durb-agenda-item5l.pdf?utm%5Fsource=openai) · [Study Details | NCT06881992 | A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism | ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06881992?aggFilters=status%3Anot+rec&cond=Pancreatic+insulin-producing+neuroendocrine+tumor+OR+%22beta+cell+neoplasm%22+OR+%22+Beta+cell+tumor%22+OR+%22+Beta+cell+tumor+of+pancreas%22+OR+%22+beta+cell+tumor+of+the+pancreas%22+OR+%22+Beta+cell+tumour%22+OR+%22+Beta+cell+tumour+of+pancreas%22+OR+%22+beta+cell+tumour+of+the+pancreas%22+OR+%22+insulin-producing+islet+cell+tumor%22+OR+%22+insulin-producing+islet+cell+tumour%22+OR+%22+insulin-producing+tumor+of+islet+cells%22+OR+%22+insulin-producing+tumor+of+the+islet+cells%22+OR+%22+insulin-producing+tumour+of+islet+cells%22+OR+%22+insulin-producing+tumour+of+the+islet+cells%22+OR+%22+pancreatic+Beta+cell+tumor%22+OR+%22+pancreatic+Beta+cell+tumour%22+OR+%22+pancreatic+insulin+producing+neoplasm%22+OR+%22+pancreatic+insulin+producing+NET%22+OR+%22+pancreatic+insulin+producing+tumor%22+OR+%22+pancreatic+insulin+producing+tumour%22+OR+%22+pancreatic+insulin-producing+tumor%22+OR+%22+pancreatic+insulin-producing+tumour%22&rank=7&viewType=Table&utm%5Fsource=openai) · [Management of Non-Islet-Cell Tumor Hypoglycemia: A Clinical Review - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/?utm%5Fsource=openai)

**Why it could work.** Interim data demonstrated that 7 of the first 8 upLIFT patients met the primary responder criterion within eight weeks and completely discontinued continuous intravenous glucose infusions.

**Why it could fail.** In the 8-patient interim cohort, one participant with metastatic colon cancer withdrew before completing therapy and died after entering hospice care.

**Recent development.** On October 5, 2026, Rezolute reported that the FDA recommended a pre-BLA meeting concerning ersodetug in congenital hyperinsulinism ([sec.gov](https://www.sec.gov/Archives/edgar/data/1509261/000110465926113503/tm2626976d1%5F8k.htm?ref=biostockinfo.com)). That formal feedback advances the regulatory strategy for the separate pediatric sunRIZE study without altering upLIFT trial execution.

**Filing flag.** One of 8 enrolled participants withdrew before completing the pivotal treatment phase and was counted as a non-responder; the filing reports the participant had Stage 4 metastatic colon cancer and died after transitioning to hospice. Ersodetug is investigational.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=RZLT&ref=biostockinfo.com)

### ZURA — Zura Bio

| CATALYST**Q4 2026**Data readout | RANK**82**           | PRICE**$4.00**\-23% 20d |
| ------------------------------- | -------------------- | ----------------------- |
| CAP**$383M**(96M sh)            | CASH**$183M**\~28 mo |                         |

**Topline data from the 247-patient Phase 2 TibuSHIELD trial of tibulizumab in moderate to severe hidradenitis suppurativa are expected in Q4 2026 (company's words; quarter-level precision).** The readout establishes whether dual cytokine inhibition improves skin lesion clearance over existing single-target biologics.

**Company.** Zura Bio is a clinical-stage immunology biotech with no commercialized products. Alongside lead candidate tibulizumab in hidradenitis suppurativa, the pipeline includes the Phase 2 TibuSURE trial in systemic sclerosis, scheduled for topline data in first-half 2027.

**Science & competition.** Tibulizumab is a dual-targeting antibody neutralizing interleukin-17A and B-cell activating factor. Rivals include Adalimumab (AbbVie, 2015 for HS), Secukinumab (Novartis, 2023), Bimekizumab (UCB, 2024), Povorcitinib (Incyte, Phase 3), and Ruxolitinib cream (Incyte, Phase 3 for mild-to-moderate HS). Standard of care relies on systemic antibiotics, surgical interventions, and adalimumab for moderate-to-severe disease.

Competition sources

Sources: [Search Orphan Drug Designations and Approvals](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=446414&utm%5Fsource=openai) · [Hidradenitis suppurativa: Diagnosis and treatment](https://www.aad.org/public/diseases/a-z/hidradenitis-suppurativa-treatment?utm%5Fsource=openai) · [Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting | Incyte](https://investor.incyte.com/news-releases/news-release-details/incyte-announces-new-positive-54-week-late-breaking-data?utm%5Fsource=openai) · [Study Details | NCT06959225 | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) | ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06959225?utm%5Fsource=openai)

**Why it could work.** Simultaneously neutralizing IL-17A and BAFF addresses both neutrophil inflammation and autoantibody pathology, potentially delivering deeper tissue clearance than single-agent IL-17 inhibitors.

**Why it could fail.** Filings omit primary endpoints, dose arms, and duration. Dual immunosuppression also increases neutropenia and severe infection risks.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=ZURA&ref=biostockinfo.com)

### NKTX — Nkarta

| CATALYST**Nov 9, 2026**Conference | RANK**82**           | PRICE**$2.25**\-23% 20d |
| --------------------------------- | -------------------- | ----------------------- |
| CAP**$161M**(72M sh)              | CASH**$217M**\~28 mo |                         |

**Nkarta presents Phase 1/2 preliminary clinical activity and safety for NKX019 in systemic sclerosis at ACR Convergence 2026 on Nov 9, 2026.** The presentation decides whether allogeneic CAR NK cells can achieve durable immune resetting in autoimmune disease.

**Company.** Nkarta is a clinical-stage biotech developing engineered natural killer cell therapies for autoimmune diseases and oncology. It has no approved products or commercial revenues. The pipeline centers on allogeneic CD19-directed cell candidates, including NKX019.

**Science & competition.** NKX019 uses donor natural killer cells engineered with a CD19 chimeric antigen receptor to deplete autoreactive B cells. Rivals include Nintedanib (Ofev) (Boehringer Ingelheim, FDA-approved, 2019 for SSc-ILD), Tocilizumab (Actemra) (Genentech/Roche, FDA-approved, 2021 for slowing lung-function decline in SSc-ILD), Anifrolumab (Saphnelo) (AstraZeneca, Phase 3 (DAISY)), and Nerandomilast (BI 1015550) (Boehringer Ingelheim, Phase 3). Standard of care includes organ-specific management, cyclophosphamide, and mycophenolate mofetil for interstitial lung complications.

Competition sources

Sources: [Search Orphan Drug Designations and Approvals](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=381212&utm%5Fsource=openai) · [NCT05925803: Systemic Sclerosis — Active, not recruiting | UniteRare | UniteRare](https://www.uniterare.org/trials/NCT05925803?utm%5Fsource=openai) · [Systemic sclerosis clinical trials: 156 recruiting studies | RareTrial](https://www.raretrial.org/diseases/systemic-sclerosis?utm%5Fsource=openai)

**Why it could work.** Donor natural killer cells enable immediate off-the-shelf administration, avoiding lengthy bespoke manufacturing and lowering risks of severe neurotoxicity or graft-versus-host disease.

**Why it could fail.** Allogeneic NK cells risk rapid host immune rejection, causing transient B-cell depletion that fails to reverse dermal and organ fibrosis.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=NKTX&ref=biostockinfo.com)

### PHAT — Phathom Pharmaceuticals

| CATALYST**fourth quarter of 2026**Data readout | RANK**79**           | PRICE**$7.25**\-13% 20d |
| ---------------------------------------------- | -------------------- | ----------------------- |
| CAP**$586M**(81M sh)                           | CASH**$172M**\~56 mo |                         |

**Phathom expects 12-week double-blind topline results from its 95-patient Phase 2 pHalcon-EoE-201 trial of VOQUEZNA in fourth quarter of 2026 (company's words; quarter-level precision).** The readout determines whether potassium-competitive acid blockade can relieve dysphagia and mucosal inflammation in eosinophilic esophagitis.

**Company.** Phathom commercializes gastrointestinal treatments. VOQUEZNA generates commercial sales for erosive esophagitis and Helicobacter pylori. Its expansion pipeline explores eosinophilic esophagitis and an on-demand non-erosive gastroesophageal reflux disease registrational study yielding data in 2028.

**Science & competition.** Vonoprazan competitively blocks potassium ions to achieve sustained gastric acid suppression. Rivals include Dupixent (dupilumab) (Regeneron / Sanofi, FDA-approved 2022; expanded to younger children in 2024), Eohilia (budesonide oral suspension) (Takeda, FDA-approved 2024; labeled for a 12-week course in patients ≥11 years), and Tezspire (tezepelumab) (Amgen / AstraZeneca, Phase 3; positive topline results announced August 2026). Standard of care comprises proton-pump inhibitors, swallowed topical steroids, elimination diets, and dupilumab.

Competition sources

Sources: [DailyMed - VOQUEZNA- vonoprazan fumarate tablet](https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0cc52ac5-77ec-4d66-a770-762a1a960914&utm%5Fsource=openai) · [Search Orphan Drug Designations and Approvals](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=599317&utm%5Fsource=openai) · [A Look at the Updated ACG Eosinophilic Esophagitis Clinical Guidelines - American College of Gastroenterology](https://gi.org/journals-publications/ebgi/eluri%5Ffeb2025/?utm%5Fsource=openai)

**Why it could work.** Potent potassium-competitive acid suppression can restore esophageal epithelial barrier integrity, potentially blocking allergen penetration and unlocking a 6-month pediatric exclusivity extension.

**Why it could fail.** Because EoE is primarily driven by Th2 allergic inflammation rather than acid reflux, gastric inhibition may fail to clear mucosal eosinophils.

**Recent development.** On September 29, 2026, Phathom initiated patient screening in pHalcon-NERD-302, a Phase 3 study evaluating on-demand dosing of VOQUEZNA in non-erosive gastroesophageal reflux disease with topline results targeted in 2028 ([phathompharma.com](https://investors.phathompharma.com/?ref=biostockinfo.com)). The trial tests an on-demand label expansion distinct from the daily scheduled dosing in eosinophilic esophagitis.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=PHAT&ref=biostockinfo.com)

### TNYA — Tenaya Therapeutics

| CATALYST**fourth quarter of the year**Data readout | RANK**78**          | PRICE**$0.58**\-9% 20d |
| -------------------------------------------------- | ------------------- | ---------------------- |
| CAP**$130M**(224M sh)                              | CASH**$63M**\~14 mo |                        |

PRIME

**Tenaya plans to present interim Cohort 2 results from the Phase 1b/2 RIDGE-1 trial of TN-401 in in fourth quarter of the year (company's words; quarter-level precision):** PRIME**.** The readout evaluates whether a higher gene therapy dose safely restores desmosomal protein expression in genetic cardiomyopathy.

**Company.** Tenaya develops genetic medicines for heart disease without commercial revenues. Its pipeline includes TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy and a research collaboration with Alnylam that generated a $10.0 million upfront payment.

**Science & competition.** TN-401 utilizes an adeno-associated virus vector to deliver a functional copy of the PKP2 gene directly into cardiac myocytes. No specific phase 3 competitors are active. Standard of care relies on exercise restriction, antiarrhythmic medications, catheter ablation, and implantable cardioverter-defibrillators.

Competition sources

Sources: [RIDGE-1 - Health Research Authority](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/ridge-1/?utm%5Fsource=openai) · [Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: An International Task Force Consensus Statement - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC4521905/?utm%5Fsource=openai)

**Why it could work.** Low-dose Cohort 1 demonstrated 100% transduction across three patients, RNA expression, an average 10% increase in PKP2 protein, and reduced electrical instability.

**Why it could fail.** Higher vector dosing at 6E13 vg/kg increases the risk of immune-mediated hepatotoxicity or myocarditis, potentially stalling late-stage trial alignment with regulators.

**Recent development.** On September 14, 2026, the FDA granted TN-401 Regenerative Medicine Advanced Therapy designation for PKP2-associated arrhythmogenic right ventricular cardiomyopathy ([gcs-web.com](https://tenayatherapeutics.gcs-web.com/news-releases/news-release-details/tenaya-therapeutics-granted-us-fda-regenerative-medicine?ref=biostockinfo.com)). The regulatory milestone provides expedited review channels for the program but does not alter clinical efficacy data.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=TNYA&ref=biostockinfo.com)

### TARA — Protara Therapeutics

| CATALYST**in 4Q 2026**Data readout | RANK**78**           | PRICE**$2.75**\-28% 20d |
| ---------------------------------- | -------------------- | ----------------------- |
| CAP**$163M**(59M sh)               | CASH**$143M**\~26 mo |                         |

**Protara expects interim results from its registrational Phase 3 THRIVE-3 trial of IV Choline Chloride in 4Q 2026 (company's words; quarter-level precision).** The analysis decides whether intravenous choline supplementation can correct deficiency and prevent liver injury in long-term parenteral nutrition.

**Company.** Protara develops therapies for rare diseases and cancer without commercialized drug sales. Its pipeline centers on IV Choline Chloride for parenteral support dependencies and clinical-stage programs in non-muscle invasive bladder cancer.

**Science & competition.** IV Choline Chloride restores circulating choline required for hepatic lipid transport and cellular membrane synthesis. Rivals include Teduglutide (Gattex) (Takeda, FDA-approved 2012), Glepaglutide (Zealand Pharma, Phase 3), and Apraglutide (Ironwood Pharmaceuticals, Phase 3; confirmatory STARS-2 trial initiated in 2026). Standard of care relies on individualized parenteral admixtures, fluid management, and teduglutide for short bowel syndrome.

Competition sources

Sources: [These highlights do not include all the information needed to use GATTEX safely and effectively. See full prescribing information for GATTEX. GATTEX® (teduglutide) for injection, for subcutaneous useInitial U.S. Approval: 2012](https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=66b69c1e-b25c-44d3-b5ff-1c1de9a516fa&type=display&utm%5Fsource=openai) · [Short Bowel Syndrome · Phase III (2024-512486-14-00) | CTIS.eu](https://ctis.eu/trial/2024-512486-14-00?utm%5Fsource=openai) · [IRONWOOD PHARMACEUTICALS, INC.\_June 30, 2026](https://www.sec.gov/Archives/edgar/data/1446847/000110465926091987/irwd-20260630x10q.htm?utm%5Fsource=openai)

**Why it could work.** Parenteral feeding formulations omit bioavailable choline, making direct physiological repletion a direct pharmacological correction for a well-documented orphan deficiency.

**Why it could fail.** Protara has not disclosed sample sizes, primary endpoints, or interim stopping boundaries, creating interpretation risk if biomarker changes appear marginal or uninformative.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=TARA&ref=biostockinfo.com)

### FBIO — Fortress Biotech

| CATALYST**late 2026**Data readout | RANK**77**               | PRICE**$2.13**\-15% 20d |
| --------------------------------- | ------------------------ | ----------------------- |
| CAP**$71M**(33M sh)               | CASH**$197M**no net burn |                         |

Filing warning

**Fortress anticipates Phase 2 trial results for Triplex in adults co-infected with HIV and cytomegalovirus in late 2026 (company's words; quarter-level precision).** The readout determines whether recombinant viral vector immunization provides durable immunological control against latent viral reactivation.

**Company.** Fortress operates as a biopharmaceutical holding company acquiring and developing clinical assets through subsidiary companies. It generates partner and subsidiary licensing revenue, holding equity in Helocyte, which develops the Triplex viral vector vaccine.

**Science & competition.** Triplex is a recombinant viral vector vaccine designed to stimulate antigen-specific T cells against cytomegalovirus. Rivals include Ganciclovir (Roche (Cytovene; generics also marketed), Approved 1989), Foscarnet (Clinigen (Foscavir), Approved 1991), Cidofovir (Gilead (Vistide), Approved 1996), Valganciclovir (Roche (Valcyte; generics also marketed), Approved 2001), Letermovir (Merck (Prevymis), Approved 2017), and Maribavir (Takeda (Livtencity), Approved 2021). Standard of care for significant infection relies on valganciclovir or intravenous ganciclovir.

Competition sources

Sources: [Cytomegalovirus Therapy: Role of Letermovir in Prophylaxis and Treatment in Transplant Recipients | Annual Reviews](https://doi.org/10.1146/annurev-med-042921-124739?utm%5Fsource=openai) · [Study Details | NCT05085366 | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05085366?aggFilters=status%3Aact&cond=CMV&rank=3&utm%5Fsource=openai) · [Cytomegalovirus Disease: Adult and Adolescent OIs | NIH](https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/cytomegalovirus?utm%5Fsource=openai)

**Why it could work.** Generating polyfunctional cellular immunity against multiple viral antigens could prevent systemic vascular inflammation and organ complications across an underserved chronic co-infection market.

**Why it could fail.** Expected data delivery has slipped repeatedly across 2026 filings from the first half to mid-year and finally to year-end, while endpoints remain undisclosed.

**Filing flag.** The expected data timing moved from first half of 2026 (March 31, 2026 filing) to mid-2026 (May 14, 2026 filing) and then to end of 2026 (August 13, 2026 filing).

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=FBIO&ref=biostockinfo.com)

### ZBIO — Zenas BioPharma

| CATALYST**4Q 2026**Data readout | RANK**77**           | PRICE**$27.26**\-12% 20d |
| ------------------------------- | -------------------- | ------------------------ |
| CAP**$1.8B**(65M sh)            | CASH**$610M**\~32 mo |                          |

Filing warning

**Zenas expects topline overall and biomarker population results from the Phase 2 SunStone trial of obexelimab in systemic lupus erythematosus in 4Q 2026 (company's words; quarter-level precision).** The data determine whether non-depleting B-cell inhibition justifies advancement into a planned Phase 3 study.

**Company.** Zenas develops targeted immunology therapies without commercial product revenue. Lead asset obexelimab is partnered with Bristol Myers Squibb in certain regions, with additional development underway in IgG4-related disease and multiple sclerosis.

**Science & competition.** Obexelimab co-engages CD19 and FcγRIIb to suppress B-cell activation while preserving baseline cell viability. Rivals include Belimumab (Benlysta) (GSK, FDA-approved 2011 for SLE; 2020 for lupus nephritis), Anifrolumab (Saphnelo) (AstraZeneca, FDA-approved 2021 for adult SLE), Voclosporin (Lupkynis) (Aurinia, FDA-approved 2021 for adult lupus nephritis), Obinutuzumab (Gazyva) (Genentech/Roche, FDA-approved 2025 for adult lupus nephritis), Ianalumab (Novartis, Phase 3 in SLE and lupus nephritis), and Litifilimab (BIIB059) (Biogen, Phase 3 in SLE). Standard care involves hydroxychloroquine, corticosteroids, and tailored immunosuppressive agents.

Competition sources

Sources: [Study Details | NCT06559163 | A Study of Obexelimab in Patients With Systemic Lupus Erythematosus | ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06559163?aggFilters=status%3Arec&cond=Lupus+Erythematosus&country=United+States&locStr=United+States&rank=4&viewType=Table&utm%5Fsource=openai) · [label](https://www.accessdata.fda.gov/drugsatfda%5Fdocs/label/2024/125370s081lbl.pdf?utm%5Fsource=openai)

**Why it could work.** Downregulating B cells through inhibitory signaling halts autoantibody secretion without cell destruction, reducing chronic immunosuppression risks and severe opportunistic infections.

**Why it could fail.** Lupus studies face high placebo response rates, and non-depleting inhibition may lack sufficient biological potency to suppress severe active disease.

**Filing flag.** The expected topline timing changed: on November 12, 2025, Zenas expected results in mid-2026; by January 5, 2026, the company expected results in 4Q 2026.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=ZBIO&ref=biostockinfo.com)

## Watchlist

### ENTA — Enanta Pharmaceuticals

| CATALYST**fourth quarter of 2026**Data readout | RANK**77**           |
| ---------------------------------------------- | -------------------- |
| PRICE**$12.50**\-4% 20d                        | CAP**$364M**(29M sh) |

Cash $201M, \~68 mo

financing filed since the cash date

Enanta expects topline data from its randomized, double-blind Phase 1 study of EDP-978 in healthy volunteers in the fourth quarter of 2026 (company's words; quarter-level precision). The single- and multiple-ascending-dose trial evaluates safety, pharmacokinetics, and serum tryptase pharmacodynamics for the oral KIT inhibitor. A clinical efficacy endpoint is not measured in this healthy-volunteer cohort.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=ENTA&ref=biostockinfo.com)

### INO — INOVIO Pharmaceuticals

| CATALYST**Oct 30, 2026**Regulatory | RANK**76**            |
| ---------------------------------- | --------------------- |
| PRICE**$1.15**\-8% 20d             | CAP**$119M**(103M sh) |

Cash unavailable

financing filed since the cash dateAccelerated Approval Priority Review BTD ODD Filing warning

INOVIO faces an FDA action date of Oct 30, 2026 for its accelerated-approval BLA of INO-3107 in recurrent respiratory papillomatosis. The submission holds Breakthrough Therapy and Priority Review designations, but the FDA flagged a preliminary review concern regarding whether adequate data were provided to support accelerated-approval eligibility. Standard care remains repetitive surgical excision of airway papillomas.

**Filing flag.** The FDA’s BLA acceptance letter identified a potential review issue: its preliminary conclusion that adequate information had not been submitted to support accelerated-approval eligibility. In August 2026, the FDA had not discussed that comment at the informal clinical meeting; feedback on confirmatory-trial design was forthcoming.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=INO&ref=biostockinfo.com)

### VYGR — Voyager Therapeutics

| CATALYST**fourth quarter of 2026**Data readout | RANK**75**           |
| ---------------------------------------------- | -------------------- |
| PRICE**$2.45**\-23% 20d                        | CAP**$151M**(62M sh) |

Cash $114M, \~11 mo

Voyager expects initial tau PET imaging efficacy data in the fourth quarter of 2026 (company's words; quarter-level precision) from its Phase 1 multiple ascending dose trial of VY7523 in early Alzheimer’s disease. The readout provides the first assessment of whether the antibody reduces pathological tau spread in the brain. The company has not disclosed the cohort sample size or specific primary endpoints in regulatory filings.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=VYGR&ref=biostockinfo.com)

### SNDX — Syndax Pharmaceuticals

| CATALYST**fourth quarter of 2026**Data readout | RANK**75**           |
| ---------------------------------------------- | -------------------- |
| PRICE**$16.99**\-7% 20d                        | CAP**$1.5B**(89M sh) |

Cash $512M, \~28 mo

Syndax expects Phase 2 MAXPIRe topline data evaluating axatilimab added to standard of care in idiopathic pulmonary fibrosis in the fourth quarter of 2026 (company's words; quarter-level precision). The 26-week study completed patient enrollment in the first quarter of 2026\. Filings do not disclose sample size or primary efficacy endpoints, while approved standard therapies remain limited to pirfenidone and nintedanib.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=SNDX&ref=biostockinfo.com)

### CGEM — Cullinan Therapeutics

| CATALYST**Nov 8, 2026**Conference | RANK**74**           |
| --------------------------------- | -------------------- |
| PRICE**$15.53**\-25% 20d          | CAP**$999M**(64M sh) |

Cash $311M, \~23 mo

Cullinan presents Phase 1 multi-dose-regimen data for its BCMAxCD3 T cell engager velinotamig in systemic lupus erythematosus at ACR Convergence on Nov 8, 2026\. The trial, conducted by partner Genrix Bio, tests whether targeted plasma cell depletion can reset autoimmune memory. Regulatory filings omit prior clinical response rates, patient cohort counts, and primary endpoints.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=CGEM&ref=biostockinfo.com)

### SLS — SELLAS Life Sciences Group

| CATALYST**Q4 2026**Data readout | RANK**74**            |
| ------------------------------- | --------------------- |
| PRICE**$11.65**+1% 20d          | CAP**$2.4B**(202M sh) |

Cash $130M, \~55 mo

SELLAS expects Phase 2 topline data for CDK9 inhibitor SLS009 (tambiciclib) in newly diagnosed first-line acute myeloid leukemia in Q4 2026 (company's words; quarter-level precision). The study had enrolled 28 of a targeted 80 patients as of August 11, 2026, evaluating individuals who become refractory to azacitidine and venetoclax. A potential flag is that enrollment remains ongoing while endpoint criteria are omitted from filings.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=SLS&ref=biostockinfo.com)

### AKBA — Akebia Therapeutics

| CATALYST**Oct 24, 2026**Conference | RANK**74**            |
| ---------------------------------- | --------------------- |
| PRICE**$0.80**\-16% 20d            | CAP**$222M**(277M sh) |

Cash $156M, no net burn

Akebia will present a study design poster for its Phase 2 open-label basket trial of ebribafusp alfa at ASN Kidney Week on Oct 24, 2026\. The study is evaluating tissue-targeted complement inhibition across IgA nephropathy, lupus nephritis, and C3 glomerulopathy after dosing its first patient in September 2026\. This conference appearance provides study design details only, with initial clinical efficacy data not expected until 2027.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=AKBA&ref=biostockinfo.com)

### EIKN — Eikon Therapeutics

| CATALYST**Oct 26, 2026**Conference | RANK**74**           |
| ---------------------------------- | -------------------- |
| PRICE**$7.47**\-16% 20d            | CAP**$405M**(54M sh) |

Cash $457M, \~21 mo

Eikon will present updated Phase 2 TeLuRide-005 data evaluating TLR 7/8 agonist EIK1001 alongside pembrolizumab and chemotherapy in non-small cell lung cancer at ESMO on Oct 26, 2026\. Prior May 2026 results showed an 11-month median response duration in non-squamous patients with manageable outpatient tolerability. Filings do not disclose total trial enrollment, randomization, or primary endpoints.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=EIKN&ref=biostockinfo.com)

### VIR — Vir Biotechnology

| CATALYST**Nov 5–Nov 9, 2026**Conference | RANK**74**            |
| --------------------------------------- | --------------------- |
| PRICE**$11.70**+10% 20d                 | CAP**$2.0B**(169M sh) |

Cash $952M, \~56 mo

Vir will deliver two oral presentations covering Phase 2 SOLSTICE data for elebsiran and tobevibart in chronic hepatitis delta at AASLD on Nov 5–Nov 9, 2026\. Prior Week 96 data demonstrated undetectable HDV RNA in 88% of combination patients on an intent-to-treat basis. The presentations evaluate virologic durability alongside translational natural killer cell remodeling ahead of Phase 3 ECLIPSE 1 topline data expected later in Q4.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=VIR&ref=biostockinfo.com)

### ACOG — Alpha Cognition

| CATALYST**Nov 5–Nov 8, 2026**Conference | RANK**74**           |
| --------------------------------------- | -------------------- |
| PRICE**$9.04**+2% 20d                   | CAP**$197M**(22M sh) |

Cash $33M, \~13 mo

Alpha Cognition will present clinical and real-world BEACON study posters evaluating approved Alzheimer’s therapy ZUNVEYL at the NEI Fall Congress from Nov 5–Nov 8, 2026\. The presentations focus on cognition, sleep patterns, activities of daily living, and psychotropic medication reduction in long-term care residents. The update provides post-marketing observational findings rather than a prospective pivotal trial readout.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=ACOG&ref=biostockinfo.com)

## The Take

This issue divides between regulatory reviews facing agency scrutiny and translational platform assets seeking clinical validation. On the regulatory front, INO faces unresolved accelerated-approval eligibility questions on INO-3107, while NRXP navigates post-inspection minor deficiency resolution for generic ketamine. In clinical data, RZLT enters its upLIFT readout heavily de-risked by interim glucose weaning, while NKTX, CGEM, and ZBIO test distinct B-cell modulation strategies in refractory autoimmune disorders. Macro conditions offer little margin for error: with the 10-year Treasury yield elevated at 5.24% and market breadth constricted to 36%, speculative capital remains selective. Asymmetry favors situations with clear, quantifiable endpoints over ambiguous updates. In this environment, clean biomarker responses and established regulatory pathways will command outsized premiums, while delayed readouts or uninformative interim updates will be discarded quickly.

*How the scanner ranks names, estimates cash and reads dates is explained in [the methodology note](https://www.biostockinfo.com/methodology/). Companies' own words and SEC filings are the only source for every date above; rivals are named from a cited web search. Not investment advice.*

## Disclaimer

For information and education only; not investment advice or a recommendation to buy or sell any security. This AI-assisted newsletter may contain errors or omissions, and catalyst dates can change. Verify details against original sources and do your own research. Biotechnology investing involves substantial risk, including loss of capital.